Literature DB >> 10080604

Prognostic value of p53 genetic changes in colorectal cancer.

U Kressner1, M Inganäs, S Byding, I Blikstad, L Påhlman, B Glimelius, G Lindmark.   

Abstract

PURPOSE: To explore whether there is a linkage between different mutations in the p53 gene in primary colorectal cancer and the risk of death from colorectal cancer in a large group of patients with long follow-up. We also compared a complementary DNA-based sequencing method and an immunohistochemical (IHC) method for detecting p53 protein overexpression in colorectal cancer.
MATERIALS AND METHODS: The entire coding region of the p53 gene was sequenced in 191 frozen tumor samples collected from January 1988 to November 1992. RNA was extracted and synthesized to cDNA. p53 was amplified by the polymerase chain reaction, and the DO-7 monoclonal antibody was used in the IHC assessments.
RESULTS: Mutations were detected in 99 samples (52%) from 189 patients. There was a significant relationship between the p53 mutational status and the cancer-specific survival time, with shorter survival time for patients who had p53 mutations than for those who did not (P = .01, log-rank test). Mutations outside the evolutionarily conserved regions were associated with the worst prognosis. Multivariate analysis showed that the presence of p53 mutations was an independent prognostic factor (relative hazard, 1.7, P = .03). There was no significant relationship between overexpression of p53 protein, as determined by IHC analysis, and cancer-specific survival.
CONCLUSION: Mutational analyses of the p53 gene, using cDNA sequencing in colorectal cancer, provide useful prognostic information. In addition, cDNA sequencing gives better prognostic information than IHC assessment of p53 protein overexpression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10080604     DOI: 10.1200/JCO.1999.17.2.593

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  32 in total

1.  MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.

Authors:  Celina García-García; Martín A Rivas; Yasir H Ibrahim; María Teresa Calvo; Albert Gris-Oliver; Olga Rodríguez; Judit Grueso; Pilar Antón; Marta Guzmán; Claudia Aura; Paolo Nuciforo; Katti Jessen; Guillem Argilés; Rodrigo Dienstmann; Andrea Bertotti; Livio Trusolino; Judit Matito; Ana Vivancos; Irene Chicote; Héctor G Palmer; Josep Tabernero; Maurizio Scaltriti; José Baselga; Violeta Serra
Journal:  Clin Cancer Res       Date:  2015-08-13       Impact factor: 12.531

2.  Impact of EGFR and p53 expressions on survival and quality of life in locally advanced oral squamous cell carcinoma patients treated with chemoradiation.

Authors:  Seema Gupta; Huma Khan; Vandana Singh Kushwaha; Nuzhat Husain; Mps Negi; Ashim Ghatak; Mlb Bhatt
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

3.  Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.

Authors:  David S Williams; Dmitri Mouradov; Clare Browne; Michelle Palmieri; Meg J Elliott; Rebecca Nightingale; Catherine G Fang; Rita Li; John M Mariadason; Ian Faragher; Ian T Jones; Leonid Churilov; Niall C Tebbutt; Peter Gibbs; Oliver M Sieber
Journal:  Mod Pathol       Date:  2019-08-30       Impact factor: 7.842

4.  p53 expression in colorectal carcinoma in relation to histopathological features in Ugandan patients.

Authors:  Peter F Rambau; Michael Odida; Henry Wabinga
Journal:  Afr Health Sci       Date:  2008-12       Impact factor: 0.927

5.  TP53 alterations and colorectal cancer predisposition in south Indian population: a case-control study.

Authors:  Gopi Krishna Singamsetty; Sravanthi Malempati; Srichandana Bhogadhi; Ravinder Kondreddy; Suresh Govatati; Naveen Kumar Tangudu; Sowdamani Govatati; Anil Kumar kuraganti; Manjula Bhanoori; Kondaiah Kassetty
Journal:  Tumour Biol       Date:  2013-10-26

6.  Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells.

Authors:  Marc R Theoret; Cyrille J Cohen; Azam V Nahvi; Lien T Ngo; Kimberly B Suri; Daniel J Powell; Mark E Dudley; Richard A Morgan; Steven A Rosenberg
Journal:  Hum Gene Ther       Date:  2008-11       Impact factor: 5.695

7.  Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.

Authors:  Mirna Lechpammer; Josip Lukac; Stanislav Lechpammer; Dujo Kovacević; Massimo Loda; Zvonko Kusić
Journal:  Int J Colorectal Dis       Date:  2003-11-21       Impact factor: 2.571

8.  Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up.

Authors:  A Suppiah; A Alabi; L Madden; J E Hartley; J R T Monson; J Greenman
Journal:  Int J Colorectal Dis       Date:  2008-03-11       Impact factor: 2.571

Review 9.  Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.

Authors:  B Klump; O Nehls; T Okech; C-J Hsieh; V Gaco; F S Gittinger; M Sarbia; F Borchard; A Greschniok; H H Gruenagel; R Porschen; M Gregor
Journal:  Int J Colorectal Dis       Date:  2003-06-21       Impact factor: 2.571

10.  Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area.

Authors:  A Syed Sameer; Shakeel ul Rehman; Arshad A Pandith; Nidda Syeed; Zaffar A Shah; Nissar A Chowdhri; Khursheed A Wani; Mushtaq A Siddiqi
Journal:  Saudi J Gastroenterol       Date:  2009 Oct-Dec       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.